|
HBV Meeting Paris: Next-generation core inhibitors demonstrate increased potency and distinct biochemical properties compared to first-generation core inhibitors
|
|
|
2022 International HBV meeting, September 18–22, 2022
Nuruddin Unchwaniwala1, Steven P Dunkelbarger2, Adam Zlotnick2,3, Karolyn Pionek4, Daniel D Loeb4, William Delaney1, Kathryn M Kitrinos1
1Assembly Biosciences, Inc., South San Francisco, CA, USA; 2Door Pharmaceuticals, LLC., Bloomington, IN, USA; 3Indiana University, Bloomington, IN, USA; 4University of Wisconsin-Madison, Madison, WI, USA
![0925221](../images/092622/092622-3/0925221.gif)
![0925222](../images/092622/092622-3/0925222.gif)
![0925223](../images/092622/092622-3/0925223.gif)
![0925224](../images/092622/092622-3/0925224.gif)
![0925225](../images/092622/092622-3/0925225.gif)
![0925226](../images/092622/092622-3/0925226.gif)
![0925227](../images/092622/092622-3/0925227.gif)
![0925229](../images/092622/092622-3/0925229.gif)
![09252210](../images/092622/092622-3/09252210.gif)
![09252211](../images/092622/092622-3/09252211.gif)
![09252212](../images/092622/092622-3/09252212.gif)
|
|
|
|
|
|
|